SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma develops an eye lens with drug pads that releases glaucoma medicine over time, for use during cataract surgery. It last closed at $31.43 on Nov 17, down 2.50% on the day. The average 12-month price target from 3 analysts is $44.00 (+40.0% from the last close), with a high of $45.00 and a low of $43.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From SGP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on SGP in the past 90 days. The average target is $44.00, with a high of $45.00 and a low of $43.00, compared with the last close of $31.43.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Citigroup | Maintained | Buy | $45 |
| Nov 13 | Stifel | Maintained | Buy | $44 |
| Nov 12 | HC Wainwright & Co. | Maintained | Buy | $43 |
| Aug 14 | Raymond James | Initiated | Buy | $39 |
Technical Analysis
The stock sits between its 20 and 50 day averages. Momentum is fading (RSI 50). The nearest support is the Pivot at $31.35, and the nearest resistance the Pivot R1 at $32.17.
| RSI (14) | 49.87 | Middle of its range | Neutral |
| MACD | 1.50 | Below its signal line | Bearish |
| Stochastic | 27.6 | Middle of its range | Neutral |
| ADX (14) | 29.8 | Trending down | |
| Williams %R | -78.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -34.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −8.8% | Change over 10 sessions | Bearish |
| ATR (14) | $2.25 | Typical daily range, 7.2% of price |
| RSI (14) | 57.82 | Middle of its range | Neutral |
| MACD | 2.10 | Above its signal line | Bullish |
| Stochastic | 69.4 | Middle of its range | Neutral |
| ADX (14) | 28.2 | Trending up | |
| Williams %R | -49.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 93.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +14.2% | Change over 10 sessions | Bullish |
| ATR (14) | $3.96 | Typical daily range, 12.6% of price |
What happened before
See how SGP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in SGP in the last 90 days.
SGP Institutional Ownership
Full report →- ▲37 buying vs 25 selling
- ▲Held by funds +0.8 pts
- ▲Funds holding +18
- ▼Superinvestors: 0 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 70 | 52 | +34.6% |
| In funds' top 10 | 4 | 3 | +33.3% |
| Held by funds | 78.9% | 78.1% | +0.8 pts |
| New / increased | 21 / 16 | 22 / 17 | −5.1% |
| Reduced / sold out | 22 / 3 | 5 / 5 | +150.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGP is in one of them and how their past SGP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SGP in an article yet. Here's the latest on the wider market.
About SpyGlass Pharma
SpyGlass Pharma is a biopharmaceutical company based in Irvine, California, that develops long lasting drug delivery products for people with chronic eye conditions. Its lead product candidate is an intraocular lens fitted with drug pads that releases bimatoprost, a medicine already approved for topical use, to lower eye pressure in patients with glaucoma or ocular hypertension. The lens is designed to be implanted during routine cataract surgery, so its main customers are cataract surgeons and the patients they treat. The product is still in clinical trials and is not yet approved for sale.
- Headquarters
- Irvine, CA
